William John Scheessele - Oct 13, 2021 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Role
Chief Commercial Officer
Signature
/s/ William John Scheessele by Dale A. Sander as Attorney-in-Fact
Stock symbol
HUMA
Transactions as of
Oct 13, 2021
Transactions value $
$0
Form type
4
Date filed
10/15/2021, 03:51 PM
Previous filing
Aug 27, 2021
Next filing
May 25, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HUMA Stock Options (right to buy) Award $0 +158K $0.00 158K Oct 13, 2021 Common Stock 158K $10.03 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The first 25% of the option becomes exercisable on August 9, 2022, after which 1/36 of the option will become exercisable on the 9th of each month through August 9, 2025.